Get the Stockscreener App
0.6906
4.08%
-0.0294
After Hours:
.73
0.0394
+5.71%
Vincerx Pharma Inc stock is currently priced at $0.6906, with a 24-hour trading volume of 441.20K.
It has seen a -4.08% decreased in the last 24 hours and a -27.32% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.7305 pivot point. If it approaches the $0.6893 support level, significant changes may occur.
Previous Close:
$0.72
Open:
$0.73
24h Volume:
441.20K
Market Cap:
$20.40M
Revenue:
-
Net Income/Loss:
$-48.85M
P/E Ratio:
-0.2606
EPS:
-2.65
Net Cash Flow:
$-46.25M
1W Performance:
-13.94%
1M Performance:
-27.32%
6M Performance:
+2.92%
1Y Performance:
-57.89%
1D Range:
$0.6828
$0.7371
52W Range:
$0.61
$9.3722
Vincerx Pharma Inc Stock (VINC) Company Profile
Name
Vincerx Pharma Inc
Sector
Industry
Phone
650 800 6676
Address
260 Sheridan Avenue, Suite 400, Palo Alto
Vincerx Pharma Inc Stock (VINC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-14-22 | Initiated | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-21 | Initiated | SVB Leerink | Outperform |
| Sep-13-21 | Initiated | Laidlaw | Buy |
| Aug-25-21 | Initiated | B. Riley Securities | Buy |
Vincerx Pharma Inc Stock (VINC) Latest News
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday? - MSN
MSN
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - The Bakersfield Californian
The Bakersfield Californian
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
GlobeNewswire
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Why Vincerx Pharma (VINC) Stock Is Falling - Vincerx Pharma (NASDAQ:VINC) - Benzinga
Benzinga
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
GlobeNewswire Inc.
Vincerx Pharma Inc Stock (VINC) Financials Data
Vincerx Pharma Inc (VINC) Net Income 2024
VINC net income (TTM) was -$48.85 million for the quarter ending September 30, 2023, a +16.06% increase year-over-year.
Vincerx Pharma Inc (VINC) Cash Flow 2024
VINC recorded a free cash flow (TTM) of -$46.25 million for the quarter ending September 30, 2023, a +19.24% increase year-over-year.
Vincerx Pharma Inc (VINC) Earnings per Share 2024
VINC earnings per share (TTM) was -$2.31 for the quarter ending September 30, 2023, a +16.91% growth year-over-year.
About Vincerx Pharma Inc
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
0.77%
1.20%
Cap:
|
Volume (24h):